The Effects of Growth Hormone Administration on ICSI Outcomes in Poor Ovarian Reserve. A Randomized Control Study

Abstract

IntroductionThe incidence of POR ranges from 9 to 24%. GH is a peptide produced from the pituitary gland. Growth hormone leads to the formation of IGF-1. GH and IGF-1 are both important in the formation of steroid hormones in the ovary.MethodsBetween 2021 to 2022, a randomized control study, in which patients were divided into, a study and a control group. Study group will receive an ICSI cycle with GH and control group will only receive ICSI. Results The mean AMH level and AFC are similar between the GH group (0.6 ± 0.22 ng/ml) and (5.73 ± 1.88) and the control group (0.61 ± 0.22 ng/ml) and (5.76 ± 1.72). The mean E2 level is significantly higher in the GH group than in the control group. Similarly, there is no significant difference in the mean number of mature follicles between the GH group and the control group. The mean number of stimulation days for the GH group (9.84 ± 0.69) is significantly lower than that of the control group (11.11 ± 0.74). The mean HMG dose for the GH group (4427.03 ± 309.48) is significantly lower than that of the control group (4998.65 ± 331.76). Out of the 37 patients in the GH group, 11 (29.73%) achieved pregnancy, while in the control group, 7 (18.92%) ConclusionThe role of GH as an adjunct in ARTs in POR women favors the increase of E2 levels on the HCG day and decreases the duration of stimulation and the gonadotropins dose.